To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
Side Letter: China PE’s returns rethink; secondaries deal deferrals; healthcare’s hype
LPs want more bang for their buck when backing Chinese managers. Plus: Secondaries buyers are using deferrals to bridge the gulf in pricing expectations; and RiverGlade rides the healthcare wave. Here's today's brief, for our valued subscribers only.
